This issue can be dividedinto two categories: innate resistance and acquired drug resistance.The latter can occur as a result of continued treatment with aromataseinhibitors in breast cancer patients.14 Consequently, there is a need for novel aromatase inhibitors, designedto mitigate side effects or drug resistance and tailored to individualpatient profiles. This evidence concerns the gene CYP19A1 and breast carcinoma.